Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

06/21/2013 | 05:03am US/Eastern
Recommend:
0

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
Recommend :
0
React to this article
Latest news
Date Title
2m ago SILVER CHEF : Dividend Reinvestment Plan
9m agoDJArgentina Budget Bill Puts 2015 Growth at 2.8%
17m ago LINEAR TECHNOLOGY : 1A, 1.5MHz, 65V Boost/Inverter DC/DC Converter
17m ago AWGA AUSTRALIAN WOOL GROWERS ASSOCIATION : aden + anais partners with The Woolmark Company to release a Pure Merino Muslin collection
17m ago PACIFIC NIUGINI : High Grade Gold from Nicholsons Drilling
18m ago BURGER KING WORLDWIDE : wants Hawaii needle lawsuit dismissed
22m ago UPI UNITED PACIFIC : LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
22m ago MAGELLAN FLAGSHIP FUND : Weekly NTA
22m ago ST JUDE MEDICAL : CardioMEMS Data Shows Pulmonary Artery Pressure Monitoring Significantly Reduces Heart Failure Hospitalizations in Patients with Chronic Kidney Disease
23m ago SAMSON OIL & GAS : Operational Advisory
Latest news
Advertisement
Hot News 
BANCO ESPIRITO SANTO : EU regulators expect Novo Banco sale to proceed as agreed
OXFORD PHARMASCIENCE : Progression of Reduced Gastric Irritation Naproxen
AVANIR PHARMACEUTICALS : Announces Positive Phase II Trial Results for AVP-923 in Treatment of Agitation in Patients with Alzheimer's Disease
IMMUNODIAGNOSTIC SYSTEMS HLDGS : Update on current trading
EKF DIAGNOSTICS : On Track To Meet Full-Year Expectations Despite Swing To Loss
Most Read News
2h ago Orange strikes 3.4 billion euros deal to buy Spain's Jazztel
2h ago GENERAL MOTORS : Exclusive: U.S. safety chief raps GM's 'flawed' culture on recalls
2h ago APPLE : releases tool to remove free U2 album
2h ago CONVERSANT : SHAREHOLDER ALERT: Brower Piven Announces Investigation Of Conversant, Inc. In Connection With The Proposed Sale Of The Company To Alliance Data Systems Corporation
1h ago Heineken's snub to SAB revives beer deal speculation
Most recommended articles
8m agoDJArgentina Budget Bill Puts 2015 Growth at 2.8%
26m ago Asian shares edge higher as investors await Fed
34m ago Insight - 'Mr. Confession' and his boss drive China's antitrust crusade
36m ago After standoff, Vale and China's Cosco both claim shipping victory
48m ago Britain slides to five-year low in E&Y's renewable energy ranking
Dynamic quotes  
ON
| OFF